260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

Key Points

• Blue Owl Capital Holdings LP purchased 260,000 Viridian Therapeutics shares worth approximately $4.8 million, giving it about 0.23% of the company and making Viridian its 23rd-largest holding.
• Analyst sentiment remains broadly positive: 13 analysts rate VRDN a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $38.93.
• Viridian reported a quarterly loss of $1.05 per share, slightly worse than estimates, while revenue of $0.28 million exceeded expectations; the company remains unprofitable, with analysts forecasting a full-year loss of $4.07 per share.

Blue Owl Capital Holdings LP purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 260,000 shares of the company's stock, valued at approximately $4,776,000. Viridian Therapeutics accounts for approximately 0.7% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 23rd largest holding. Blue Owl Capital Holdings LP owned about 0.23% of Viridian Therapeutics as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in shares of Viridian Therapeutics in the 4th quarter worth approximately $36,000. KBC Group NV acquired a new stake in Viridian Therapeutics in the 1st quarter valued at $34,000. State of Wyoming bought a new stake in Viridian Therapeutics in the second quarter valued at $43,000. Larson Financial Group LLC acquired a new position in Viridian Therapeutics during the third quarter worth $52,000. Finally, US Bancorp DE raised its stake in Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company's stock worth $53,000 after acquiring an additional 463 shares in the last quarter.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

VRDN has been the topic of several recent analyst reports. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a research note on Friday, May 15th. Truist Financial lifted their price target on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wells Fargo & Company upgraded shares of Viridian Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $20.00 to $31.00 in a research report on Monday, June 29th. Wall Street Zen cut shares of Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Finally, Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.93.

Viridian Therapeutics Stock Performance

VRDN stock opened at $24.50 on Friday. The company has a 50 day moving average price of $19.66 and a 200 day moving average price of $20.97. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. The stock has a market capitalization of $2.78 billion, a PE ratio of -7.27 and a beta of 0.91.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.02). The firm had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. Analysts forecast that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source